China has sharply restricted investigator-initiated biotech clinical trials after patient deaths, slowing what had been a surge of controversial studies. The change leaves rare disease families with fewer trial options and creates uncertainty for US investors exposed to China’s biotech sector. It matters because tighter oversight may improve safety but could also delay access and complicate cross-border investment.
Clinical TrialsEthics & SafetyCell Therapy IndustryRead more →
Two industry experts, Sun Chau Siu and Kaisong Zhou, offer a point of view on what biotech licensing actually delivers, focusing on the often-overlooked difficulties of transferring intellectual property between organizations. Their commentary draws attention to execution challenges that sit beyond the deal terms themselves. For professionals working in licensing or technology transfer, the piece serves as a reminder that securing rights is only part of the task.
Revolution Medicines’ pancreatic cancer drug Rasonque has gotten off to an exceptionally strong commercial start, with its debut described as one of the best oncology launches in history. The early uptake matters because it signals rapid adoption in a difficult-to-treat cancer and could meaningfully shape expectations for the company’s commercial prospects.
India has proposed rules that would require regulators to immediately suspend manufacturing licenses when government testing shows a drug fails quality standards. For industry professionals, the move signals tighter enforcement and higher compliance risk for manufacturers, with potential implications for supply continuity and quality assurance.
Clinical TrialsEthics & SafetyCell Therapy IndustryRead more →
Senator Bernie Sanders, a longtime critic of the pharmaceutical industry, is positioned to play a significant role in shaping the legislation that funds the FDA. The report says he could use that influence during drafting to press for reforms. Because FDA funding measures often carry substantive policy changes, his involvement matters for drugmakers, regulators, and others tracking the agency's direction.
Regulation & ApprovalCell Therapy IndustryRead more →
Rose BioSolutions CEO David Enloe argues that developers of advanced therapies should rethink how they work with contract development and manufacturing organizations, moving beyond a transactional outsourcing model. He contends that complex biologics and cell and gene therapies require earlier joint problem-solving, deeper scientific collaboration, and shared accountability between sponsors and manufacturers. The commentary matters for biotech leaders choosing manufacturing partners, since misaligned incentives and late-stage handoffs can translate into costly delays and quality risk.
Regulation & ApprovalCell Therapy IndustryRead more →
An oral therapy for obstructive sleep apnea that targets multiple pathways is positioned to add to existing treatment choices. It is expected to improve patient compliance and may lead to better outcomes, though the excerpt does not specify trial results or regulatory status.
Nicola Ambler gave an interview sharing her main takeaways from Biotech Week Boston 2026, held 22–25 September in Boston, Massachusetts. She reflected on a Women in Bio panel she participated in, which examined how professionals can build lasting careers by aligning their values with their work as policy conditions shift. The discussion speaks to biotech professionals navigating career decisions in an evolving regulatory and policy environment.
The article discusses mass spectrometry-based exposomics as a promising approach for measuring environmental exposures and understanding their impact on health. By profiling the chemistry around us, the method could help researchers link exposures to disease and improve environmental health risk assessment. It matters to professionals because better exposure measurement may strengthen studies of how environment shapes health outcomes.
Glycosylation control is shifting from a secondary analytical concern to a core development priority for complex biologics. This changes expectations for contract development and manufacturing organizations, which are now being asked to address glycosylation earlier rather than after the fact. The article presents quality-by-design methods as a way for CDMOs to move these controls upstream efficiently, making process development more proactive and better aligned with complex biologic requirements.
Tissue engineering is advancing on several fronts, with personalized grafts, bioinks for printing living structures, and off-the-shelf tissue products moving regenerative medicine closer to wider clinical use. The shift matters because it suggests the field is progressing from bespoke laboratory work toward approaches that could be manufactured and distributed more broadly. For professionals, the emphasis on off-the-shelf availability points to the practical challenges of scalability, consistency, and regulatory readiness that will determine clinical adoption.
Regenerative MedicineEthics & SafetyCell Therapy IndustryRead more →
The nonprofit biotech has in-licensed its first gene therapy and plans to expand its pipeline. It evaluates candidates based on unmet medical need, clinical evidence of safety and efficacy, and fit with institutional partners. Its funding model combines seed investment with commercial revenue and non-traditional sources, making the first license a signal that the accelerator’s approach is moving into execution and could support more rare-disease therapies.
Clinical TrialsEthics & SafetyCell Therapy IndustryRead more →
A new expert perspective examines how delivery technologies will influence the future of cell and gene therapy. Anthony Blaszczyk, a principal scientist at USP, offers insights on the delivery challenges and opportunities that may shape the field. For professional readers, the commentary underscores that therapeutic payloads alone are not enough and that delivery innovation is central to advancing these therapies.
At the European Society of Gene and Cell Therapy’s 33rd annual congress in Hamburg, teams from FUJIFILM Biosciences and Terumo Blood and Cell Technologies shared an update on their ongoing partnership. They discussed how pairing their respective capabilities is intended to support gene and cell therapy workflows. For professionals, the update signals continued cross-industry collaboration around enabling technologies in this rapidly evolving field.